DT07 Rec'd PCT/PTO 0 4 MAR 2005.

PTO-1390 (Rev. 12-2004) d for use through 3/31/2007. OMB 0651-0021 U.S. Patent and Tra Office; U.S. DEPARTMENT OF COMMERCE action Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LÉTTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

Under the Paperwork Re

ATTTORNEY'S DOCKET NUMBER 3092 US0P

U.S. APPLICATION NO

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/JP03/11308 September 4, 2003 September 6, 2002

TITLE OF INVENTION FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF APPLICANT(S) FOR DO/EO/US Kazumasa HAMAMURA; Shigekazu SASAKI; Yuichiro AMANO; Junichi SAKAMOTO; Kohji FUKATSU Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. $\overline{\mathbf{v}}$ The US has been elected (Article 31). \square A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). .6. [V] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. . has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 10. Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. Cited References An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). Return Postcard; Certificate of Express Mailing; PCT Request; Cover Page International Application; Forms PCT/IB/301, 304, 306, 308, Other items or information: 332; ISR

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

LICATION NO. (if known, see 37 CER.4.5)

INTERNATIONAL ABOUT ACTIONAL ABO

U.S. APPLICAT	TION NO. (if known, see 5	37 CF E 4 .5)	INTERNATIONAL AP	PLICATION NO.	ATTORNEY'S DOC	KET NUMBER
	.0/5265	U	PCT/JP03/1130	3	3092 US0P	
21. The following	ng fees are submitted:					
a) Basic national fee\$300.00					\$	
b) Examination fee\$200.00					\$	
C) Search fee\$500.00					\$	
TOTAL OF ABOVE CALCULATIONS = \$1000.00					\$ 1,000.00	
listing or cor		ed in an ele	d in paper over 100 sheets (e ctronic medium). The fee is \$			
Total Sheets			Number of each additional 50 or fraction thereof (round up to a whole number)			
467 - 100 =	367 /50 =	7		x \$250.00	\$ 1,750.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					\$	
CLAIMS	NUMBER FI	LED	NUMBER EXTRA	RATE	\$	
Total claims	44	- 20 =	24	× \$50.00	\$ 1,200.00	
Independent clai	ims 1	- 3 =	0	× \$200.00	\$ 0	<u> </u>
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00					\$	<u> </u>
TOTAL OF ABOVE CALCULATIONS =					\$ 3,950.00	·
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.					\$	
SUBTOTAL =					\$ 3,950.00	
_	•	he English t	ranslation later than 30 mont		\$	
claimed priority date (37 CFR 1.492(f)). + TOTAL NATIONAL FEE =					\$ 3,950.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied					+ 3,330.00	
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property					\$	
TOTAL FEES ENCLOSED =					\$ 3,950.00	
	•				Amount to be refunded:	\$
:					Amount to be charged:	\$ 3,950.00
a. A chec	ck in the amount of \$		to cover the abo	ve fees is enclosed		
a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 500799 in the amount of \$ 3,950.00 to cover the above fees.						
A dupl	icate copy of this sheet is	s enclosed.	in the amount or s	5 <u>-7-7-7-</u> to to	over the above fees.	
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. 500799. A duplicate copy of this sheet is enclosed.						
			ARNING: Information on this fard information and authoriza		olic. Credit card informat	tion should not
	n appropriate time limit		CFR 1.495 has not been met on to pending status.	t, a petition to revive	(37 CFR 1.137(a) or (b)) must be filed
SEND ALL COR	RESPONDENCE TO:			1///	1/ 0	•
Mark Chao, P	h.D., JD					
Takeda Pharmaceuticals North America, Inc					Nh Dh D - 10	
475 Half Day Road					Chao, Ph.D., JD	<u></u>
Lincolnshire, IL 60069 USA NAME					7,293	
(847)383-3372 fax (847)383-3409					ON NUMBER	
					er No. 23,115	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

PTO1 Rec'd PCT/PT 0 4 MAR 2005

tba

Application No.:

Based on PCT/JP03/11308

Art Unit:

tba

Filed:

Intl. Filing 04 SEPTEMBER 2003

Examiner:

1st Inventor:

Kazumasa HAMAMURA

Allowed:

For:

Furan or Thiophene Derivative and Medicinal Use

Thereof

Batch:

Atty. Dkt. No.

3092 US0P

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 524907703 US

DATE IN:

March 4, 2005

Itemized Papers/Items:

- 1. This Certificate of Express Mailing and Return Postcard (2 pages)
- 2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
- 3. Specification total pages (467) including Claims 1-51 (pages 453-465, Abstract (1 page), and Sequence Listing (4 pages)
- 4. PCT Request Form (6 pages)
- 5. Copies of Forms PCT/IB/301, 304, 306, 308, 332 (7 pages)
- 6. Copy of Cover Page International Application (WO 2004/022551) (1 page)
- 7. Copy of International Search Report (4 pages)
- 8. Preliminary Amendment (16 pages)
- 9. Submission of Sequence Listing Requirements (1 page), CRF of Sequence Listing (2 pages), and IBM PC/AT format disk containing the CRF of the Sequence Listing.

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP PCT

P.O. BOX 1450 Commissioner for Patents

Alexandria, VA 22313-1450

on this date, 3/4/05

Dated: 3/4/05

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA